Treatment Benefits of the remedē® System Sustained Through 36 Months in Patients with Central Sleep Apnea
Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study
July 10, 2019
Respicardia Also Initiates 500-Patient Prospective, Global, Single-Arm Longitudinal Study
October 20, 2020
Trial results showed consistent improvement in sleep disordered breathing, arousals, sleep architecture, and daytime sleepiness through 5 years.
January 6, 2020
The first general hospital in Texas to treat a patient with the remedē® System
June 1, 2020
Respicardia, Inc. announced today that Richard L. Roudebush VA Medical Center in Indianapolis is the first center in Indiana to treat patients with the remedē® System, an implantable device that uses phrenic nerve stimulation to treat central sleep apnea (CSA).
October 10, 2017
Breakthrough Treatment of Moderate to Severe Central Sleep Apnea in Adult Patients Now Available